Sharma Natraj Kannan
About Sharma Natraj Kannan
Data last updated:
Sharma Natraj Kannan has 20 years in corporate governance. Holds Partner and Director roles. Currently with 4 companies, including Maxximuz Partners Llp and Sequent Scientific Limited. Formerly with 10 companies, such as Solzen Urja Private Limited and Positiveedge Technology Private Limited. Engaged in General Business, Technology. Contributes to corporate operations. The 3 current companies with reported revenue have a combined latest revenue of ₹1,349 Cr; the largest is Renserv Global Private Limited at ₹749 Cr (FY 2025).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
 Renserv Global Private Limited U74999DL2019PTC348911 | Director | 31 Mar 2025 | 2019 | ₹749 Cr (FY 2025) | Active |
 Symbio Generrics India Private Limited U74990KA2011PTC184231 | Director | 19 Sep 2022 | 2011 | ₹435 Cr (FY 2025) | Active |
 Renew Akshay Urja Limited U40300DL2015PLC275651 | Director | 29 Jan 2018 | 2015 | ₹165 Cr (FY 2025) | Active |
 Maxximuz Partners Llp AAA-4349 | Partner | 08 Sep 2018 | 2011 | – | Under Process Of Striking Off |
Previous companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Solzen Urja Private Limited U40300DL2019PTC347300 | Director | 01 Jun 2022 | 2019 | ₹177 Cr (FY 2026) | Active |
 Positiveedge Technology Private Limited U72200KA2008PTC045294 | Additional Director | 24 Oct 2009 | 2008 | ₹18.34 Cr (FY 2024) | Active |
| Renew Wind Energy (Ap) Private Limited U40106DL2012PTC242719 | Director | 28 Nov 2018 | 2012 | ₹81.53 Cr (FY 2025) | Active |
| Renew Wind Energy (Karnataka) Private Limited U40109DL2012PTC235990 | Director | 28 Nov 2018 | 2012 | ₹139 Cr (FY 2025) | Active |
 Strides Pharma Science Limited L24230MH1990PLC057062 | Company Secretary | 08 May 2006 | 1990 | ₹5,009 Cr (FY 2026) | Active |
| Renew Wind Energy (Jath) Limited U40101DL2012PLC236227 | Director | 15 Feb 2017 | 2012 | ₹86.00 Cr (FY 2025) | Active |
| Partner | 27 Nov 2013 | 2013 | – | Active | |
 Sequent Scientific Limited U24110MH2002PLC136868 | Director | 31 Mar 2006 | 2002 | – | Amalgamated |
| Grandix Laboratories Limited U24232TN2001PLC047875 | Director | 28 Sep 2007 | 2001 | – | Amalgamated |
| Quantum Remedies Private Limited U24296KA2008PTC045588 | Director | 12 Mar 2008 | 2008 | – | Amalgamated |
Explore Director's current and past company associations Uncover their professional journey today!
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Sharma Natraj Kannan
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sharma Natraj Kannan
Sharma Natraj Kannan has 20 years in corporate governance. Holds Partner and Director roles. Currently with 4 companies, including Maxximuz Partners Llp and Sequent Scientific Limited. Formerly with 10 companies, such as Solzen Urja Private Limited and Positiveedge Technology Private Limited. Engaged in General Business, Technology. Contributes to corporate operations. The 3 current companies with reported revenue have a combined latest revenue of ₹1,349 Cr; the largest is Renserv Global Private Limited at ₹749 Cr (FY 2025).
Sharma Natraj Kannan is associated with 4 companies as Partner and Director, including Renserv Global Private Limited (₹749 Cr), Symbio Generrics India Private Limited (₹435 Cr), Renew Akshay Urja Limited (₹165 Cr).
Sharma Natraj Kannan has expertise in General Business, Technology.
Sharma Natraj Kannan has 20 years in corporate governance.
By reported revenue, the largest current company of Sharma Natraj Kannan is Renserv Global Private Limited, with revenue of ₹749 Cr (FY 2025).
The 3 current companies of Sharma Natraj Kannan that report revenue have a combined latest revenue of ₹1,349 Cr.
Sharma Natraj Kannan currently holds positions at 4 companies: Renserv Global Private Limited (₹749 Cr), Symbio Generrics India Private Limited (₹435 Cr), Renew Akshay Urja Limited (₹165 Cr), Maxximuz Partners Llp.